Table 1 General information for participants
Characteristic | Biomarker screening | Biomarker validation | Clinical validation | ||||||
|---|---|---|---|---|---|---|---|---|---|
ATB | LTBI | CON | ATB | LTBI | CON | ATB | LTBI | CON | |
Number (no.) of participants | 28 | 34 | 26 | 76 | 69 | 71 | 91 | 24 | 79 |
Median age (range) | 46 (26–55) | 43 (15–62) | 39 (21–58) | 45 (18–72) | 41 (19–67) | 43 (21–64) | 42 (27–69) | 40 (23–74) | 39 (21–71) |
Males, no. (%) | 16 (57.1%) | 15 (44.1%) | 12 (46.2%) | 42 (55.3%) | 32 (46.4%) | 35 (49.3%) | 54 (59.3%) | 13 (54.2%) | 42 (53.2%) |
HIV infected, no. (%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (2.6%) | 0 (0%) | 0 (0%) | 1 (1.1%) | 0 (0%) | 0 (0%) |
BCG status | |||||||||
 Vaccinated | 17 (60.7%) | 25 (73.5%) | 23 (88.5%) | 56 (73.7%) | 55 (79.7%) | 59 (83.1%) | 58 (63.7%) | 17 (70.8%) | 54 (68.4%) |
 Unvaccinated | 6 (21.4%) | 5 (14.7%) | 2 (7.7%) | 17 (22.4%) | 12 (17.4%) | 8 (11.3%) | 29 (31.9%) | 5 (20.8%) | 20 (25.3%) |
 Unknown | 5 (17.9%) | 4 (14.3%) | 1 (3.8%) | 3 (3.9%) | 2 (2.9%) | 4 (5.6%) | 4 (4.4%) | 2 (8.3%) | 5 (6.3%) |
QFT results | |||||||||
 Negative | 3 (10.7%) | 0 (0%) | 26 (100%) | 10 (13.2%) | 0 (0%) | 71 (100%) | 17 (18.7%) | 0 (0%) | 79 (100%) |
 Positive | 25 (89.3%) | 34 (100%) | 0 (0%) | 66 (86.8%) | 69 (100%) | 0 (0%) | 74 (81.3%) | 24 (100%) | 0 (0%) |
 Extrapulmonary TB | 4 (14.3%) | – | – | 30 (39.5%) | – | – | 13 (27.7%) | – | – |
Microbiologic test | |||||||||
 AFB positive | 23 (82.1%) | – | – | 60 (78.9%) | – | – | 66 (72.5%) | – | – |
 Culture positive | 20 (71.4%) | – | – | 55 (72.4%) | – | – | 56 (61.5%) | – | – |